Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SciSparcSPRC +0.15%39 10-Year RORE % is 1.24 as of Dec. 2025. GuruFocus rates SPRC with a GF Score™ of 39/100 and a GF Value™ of $3.03 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 621 Biotechnology companies, SciSparc ranks better than 68.76% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
SciSparc's 10-Year RORE % for the quarter that ended in Dec. 2025 was 1.24%.
The industry rank for SciSparc's 10-Year RORE % or its related term are showing as below:
SPRC's 10-Year RORE % is ranked better than 68.76% of 621
companies
in the Biotechnology industry
Industry Median: -7.11
vs SPRC: 1.24
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
SciSparc 10-Year RORE % Related Terms
SciSparc 10-Year RORE % Historical Data
* Premium members only.
The historical data trend for SciSparc's 10-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SPRC vs ACUT, ONCO, PPCB: 10-Year RORE % Comparison
For the Biotechnology subindustry, SciSparc's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SciSparc 10-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SciSparc's 10-Year RORE % distribution charts can be found below:
* The bar in red indicates where SciSparc's 10-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 10-year before.
SciSparc (SPRC) has a 10-Year RORE % of 1.24 as of Dec. 2025. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on SciSparc and its competitors. According to the industry distribution chart, SciSparc ranks #194 out of 621 companies in the Biotechnology industry, placing it in the top 31.2%.
Is SciSparc's 10-Year RORE % too high?
SciSparc's current 10-Year RORE % is 1.24. Based on the distribution chart, SciSparc ranks #194 out of 621 companies in the Biotechnology industry, which is above the industry midpoint. Overall, SciSparc has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SciSparc's 10-Year RORE % compare to ACUT and ONCO?
According to the Biotechnology industry distribution chart, SciSparc ranks #194 out of 621 companies for 10-Year RORE %. This puts SciSparc in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Biotechnology company?
A good 10-Year RORE % depends on the Biotechnology industry context. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on SciSparc and its competitors. SciSparc's current 10-Year RORE % is 1.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SciSparc stock overvalued right now?
Based on GuruFocus' analysis, SciSparc (SPRC) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.03, compared to a current price of $6.66 — trading 119.8% above its estimated fair value. The current 10-Year RORE % is 1.24. SciSparc's overall GF Score™ is 39/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For SciSparc (SPRC), the current 10-Year RORE % is 1.24 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SciSparc (SPRC) Overvalued in 2026?
Based on GuruFocus' analysis, SciSparc stock appears to be overvalued.
The current stock price of $6.66 is trading 119.8% above its estimated GF Value™ of $3.03.
GuruFocus considers SciSparc to be Significantly Overvalued.
Key valuation signals for SPRC:
10-Year RORE %: 1.24
GF Value™: $3.03 vs. price of $6.66 (119.8% above fair value)
No single metric tells the full story. See the SPRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two operating reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
39GF Score
Get the complete analysis for SPRC
10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPRC has been successfully added to your 
